scholarly journals Programmed death 1 monoclonal antibody helped to treat mixed chimeric and reactivation of Epstein-Barr virus in a patient with adult-onset chronic active Epstein-Barr virus infection after allogeneic hematopoietic stem cell transplantation

Medicine ◽  
2022 ◽  
Vol 101 (2) ◽  
pp. e28542
Author(s):  
Yahong You ◽  
Jingshi Wang ◽  
Zhao Wang
Keyword(s):  
Monoclonal Antibody ◽  
Epstein Barr Virus ◽  
Epstein Barr Virus Infection ◽  
Adult Onset ◽  
Hematopoietic Stem ◽  
Barr Virus ◽  
Programmed Death ◽  
Programmed Death 1 ◽  
Epstein Barr ◽  
Barr Virus Infection

A case of chronic active Epstein–Barr virus infection mimicking adult-onset Still’s disease

2013 ◽  
Vol 23 (1) ◽  
pp. 162-166 ◽  
Author(s):  
Katsunobu Yoshioka ◽  
Hiroko Fukushima ◽  
Naomi Ishii ◽  
Akiko Kita ◽  
Yusuke Hanioka ◽  
...  
Keyword(s):  
Virus Infection ◽  
Epstein Barr Virus ◽  
Adult Onset Still’S Disease ◽  
Epstein Barr Virus Infection ◽  
Adult Onset ◽  
Still’S Disease ◽  
Barr Virus ◽  
Epstein Barr ◽  
Barr Virus Infection ◽  
Adult Onset Still's Disease

scholarly journals Clinical and Virological Characteristics of 15 Patients with Chronic Active Epstein‐Barr Virus Infection Treated with Hematopoietic Stem Cell Transplantation

2008 ◽  
Vol 46 (10) ◽  
pp. 1525-1534 ◽  
Author(s):  
Kensei Gotoh ◽  
Yoshinori Ito ◽  
Yukiko Shibata‐Watanabe ◽  
Jun‐ichi Kawada ◽  
Yoshiyuki Takahashi ◽  
...  
Keyword(s):  
Stem Cell ◽  
Hematopoietic Stem Cell Transplantation ◽  
Virus Infection ◽  
Stem Cell Transplantation ◽  
Epstein Barr Virus ◽  
Epstein Barr Virus Infection ◽  
Hematopoietic Stem ◽  
Barr Virus ◽  
Epstein Barr ◽  
Barr Virus Infection

scholarly journals Outcome of L-DEP Regimen for Treatment of Pediatric Chronic Active Epstein-Barr Virus Infection

2021 ◽  
Author(s):  
Honghao Ma ◽  
Liping Zhang ◽  
Ang Wei ◽  
Jun Yang ◽  
Dong Wang ◽  
...  
Keyword(s):  
Virus Infection ◽  
Clinical Response ◽  
Virological Response ◽  
Epstein Barr Virus ◽  
Survival Rates ◽  
Epstein Barr Virus Infection ◽  
Hematopoietic Stem ◽  
Barr Virus ◽  
Epstein Barr ◽  
Barr Virus Infection

Abstract Purpose We intended to investigate the clinical features of pediatric patients with chronic active Epstein-Barr virus infection (CAEBV) and effectiveness of the L-DEP regimen before HSCT (hematopoietic stem cell transplantation).Methods A retrospective analysis was performed on 35 patients with CAEBV at Beijing Children’s Hospital from January 2016 to January 2020. The efficacy and adverse events of the L-DEP regimen were evaluated.Results The median age of 35 patients was 7.0 years (range 2.5-17.5 years). 28 patients achieved clinical response (80.0%, 22 in clinical CR, 6 in clinical PR) after L-DEP. In terms of virological response, 7 patients (20%) were assessed as virological CR and 23 patients (65.7%) were virological PR. Finally, 29 patients underwent allo-HSCT. Median survival time was 18 months (2-50 months). The 3-year overall survival rates in patients treated with chemotherapy only (n=6), chemotherapy followed by HSCT (n=25) were 33.3% and 75.4%, respectively. After L-DEP 1st treatment, the amount of EBV-DNA loads in blood and plasma were significantly reduced than that before chemotherapy (median: 4.29×105 vs. 1.84×106, Mann-Whitney U：P=0.0004; 5.00×102 vs. 3.17×103, Mann-Whitney U：P=0.003). And, compared with liver and spleen size before chemotherapy, the size of liver and spleen shrank significantly after L-DEP 2nd (median 3.8cm vs. 1.9cm, P=0.003; 3.8cm vs. 0cm, P＜0.008). In addition, after L-DEP treatment, there was no difference in clinical or virological response rate whether HLH was accompanied or not (clinical response: 77.3% vs. 84.6%：P=0.689; virological response: 90.9% vs. 76.9%, P=0.337). Conclusion L-DEP regimen is an effective therapy in treating CAEBV for bridging to allo-HSCT.

Clinical features of adult-onset chronic active Epstein–Barr virus infection: a retrospective analysis

2011 ◽  
Vol 93 (5) ◽  
pp. 602-609 ◽  
Author(s):  
Ayako Arai ◽  
Ken-Ichi Imadome ◽  
Yuko Watanabe ◽  
Mayumi Yoshimori ◽  
Takatoshi Koyama ◽  
...  
Keyword(s):  
Virus Infection ◽  
Retrospective Analysis ◽  
Clinical Features ◽  
Epstein Barr Virus ◽  
Epstein Barr Virus Infection ◽  
Adult Onset ◽  
Barr Virus ◽  
Epstein Barr ◽  
Barr Virus Infection

scholarly journals Rituximab in the Treatment of Epstein-Barr Virus Infection after hematopoietic stem cell Transplantation in Children

Blood ◽  
2014 ◽  
Vol 124 (21) ◽  
pp. 5892-5892
Author(s):  
Zhiyong Peng ◽  
Chunfu Li ◽  
Yuelin He
Keyword(s):  
Stem Cell ◽  
Epstein Barr Virus ◽  
Epstein Barr Virus Infection ◽  
Hematopoietic Stem ◽  
Viral Loads ◽  
Barr Virus ◽  
Ebv Infection ◽  
Infection Disease ◽  
Epstein Barr ◽  
Barr Virus Infection

Abstract OBJECTIVE: To investigate the efficacy and safety of Rituximab on Epstein-Barr virus infection disease after allogeneic hematopoietic stem-cell transplantation (allo-HSCT) in children. METHODS: A retrospective analysis was performed based on clinical data of 25 children with median age of 6 years, (3~14 years) diagnosed as EBV infection and received Rituximab from Jan. 2012 to Jun. 2014 in our center. Of them, 3 patients were diagnosed as post-transplant lymphoproliferative disorders (PTLD). All patients received Rituximab at dose of 375 mg/m2 once a week for 4 sequence weeks or discontinued therapy when EBV viral loads was <500 copies/mL two times consecutively. The complete remission (CR) was defined as EBV viral loads <500 copies/mL consecutively at least two time and without any related clinical symptoms. Side effects during infusion were evaluated by Common Terminology Criteria for Adverse Events. RESULTS: The median EBV-infection time was on day 70 (18~200) after HSCT. Each of patients received a median of 2 (1~4) infusions. There were no severe side effects during the infusion of Rituximab. The cumulative complete remission (CR) rate were 88% in total. The CR rate was 56.0±9.9 %, 80.0±8.0%, 84.0±7.3%, and 88.0±6.5%, respectively, in 1st, 2nd, 3rd, and 4th week. Two patients died, one due to infections and the other died of hepatitis while receiving therapy. The CR rate was 100% in patients with PTLD (3/3). CONCLUSIONS: These data suggest Rituximab is safe and effective when treating children with EBV infection disease after allo-HSCT. Disclosures No relevant conflicts of interest to declare.

Sign in / Sign up

Export Citation Format

Share Document